(1R,4R)-2,5-二氮杂双环[2.2.1]庚烷 | 672-28-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: (1R,4R)-2,5-二氮杂双环[2.2.1]庚烷
• 中文别名: 2,5-二氮杂双环[2.2.1]庚烷
• 英文名称: 2,5-diazabicycloheptane
• 英文别名: 2,5-Diaza-bicyclo<2.2.1>heptan；2,5-diaza-bicyclo[2.2.1]heptane；2,5-Diazabicyclo[2.2.1]heptane
• CAS: 672-28-6
• 化学式: C₅H₁₀N₂
• 分子量: 98.1478
• InChiKey: UKHJNJFJCGBKSF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  (1R,4R)-2,5-二氮杂双环[2.2.1]庚烷 以 1,2-二氯乙烷 、 正丁醇 为溶剂， 反应 18.0h， 生成 5-(3-Trifluoromethyl-pyridin-2-yl)-2,5-diaza-bicyclo[2.2.1]heptane-2-carboxylic acid (4-trifluoromethyl-phenyl)-amide
  参考文献：
  名称：

  高亲和力TRPV1（VR1）香草类受体拮抗剂4-（3-三氟甲基吡啶-2-基）哌嗪-1-甲酸（5-三氟甲基吡啶-2-基）酰胺的鉴定和生物学评估。

  摘要：

  使用重组人TRPV1受体的高通量筛选用于鉴定一系列吡啶基哌嗪脲（3）作为TRPV1香草受体配体。通过平行合成对结构-活性关系的探索，确定了拮抗作用的基本药效学元素，可以通过靶向合成进一步优化以提供有效的口服生物利用度和选择性的TRPV1调节剂41，在几种体内模型中具有活性。

  DOI：

  10.1021/jm0495071

文献信息

• The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors
  作者：Christopher L. Hamblett、Joey L. Methot、Dawn M. Mampreian、David L. Sloman、Matthew G. Stanton、Astrid M. Kral、Judith C. Fleming、Jonathan C. Cruz、Melissa Chenard、Nicole Ozerova、Anna M. Hitz、Hongmei Wang、Sujal V. Deshmukh、Naim Nazef、Andreas Harsch、Bethany Hughes、William K. Dahlberg、Alex A. Szewczak、Richard E. Middleton、Ralph T. Mosley、J. Paul Secrist、Thomas A. Miller

  DOI：10.1016/j.bmcl.2007.08.023

  日期：2007.10

  series of histone deacetylase inhibitors within the benzamide structural class. Extensive exploration around the nicotinamide core led to the discovery of a class I selective HDAC inhibitor that possesses excellent intrinsic and cell-based potency, acceptable ancillary pharmacology, favorable pharmacokinetics, sustained pharmacodynamics in vitro, and achieves in vivo efficacy in an HCT116 xenograft

  该交流强调了在苯甲酰胺结构类别内烟酰胺系列组蛋白脱乙酰基酶抑制剂的开发。围绕烟酰胺核心的广泛探索导致发现I类选择性HDAC抑制剂，该抑制剂具有出色的内在和基于细胞的效能，可接受的辅助药理学，良好的药代动力学，体外持续的药效学，并在HCT116异种移植模型中实现了体内功效。
• A2a adenosine receptor antagonists
  申请人：Peng Hairuo

  公开号：US20070173505A1

  公开（公告）日：2007-07-26

  The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A 2a adenosine receptor, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including Parkinson's disease. In one embodiment, the invention features a compound of formula (I).

  本发明基于发现，式（I）化合物具有意外的高亲和力，可用作A2a腺苷受体的拮抗剂，用于预防和/或治疗多种疾病，包括帕金森病。在一种实施例中，本发明涉及式（I）化合物。
• Benzoxepin PI3K inhibitor compounds and methods of use
  申请人：F. Hoffman-La Roche AG

  公开号：US08263633B2

  公开（公告）日：2012-09-11

  Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and where (i) X1 is N and X2 is S, (ii) X1 is S and X2 is N, (iii) X1 is CR7 and X2 is S, (iv) X1 is S and X2 is CR7; (v) X1 is NR8 and X2 is N, (vi) X1 is N and X2 is NR8, (vii) X1 is CR7 and X2 is O, (viii) X1 is O and X2 is CR7, (ix) X1 is CR7 and X2 is C(R7)2, (x) X1 is C(R7)2 and X2 is CR7; (xi) X1 is N and X2 is O, or (xii) X1 is O and X2 is N, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  公式I中的苯并噁唑化合物，包括立体异构体、几何异构体、互变异构体、溶剂化物、代谢物和药学上可接受的盐，其中：Z1为CR1或N；Z2为CR2或N；Z3为CR3或N；Z4为CR4或N；其中（i）X1为N且X2为S，（ii）X1为S且X2为N，（iii）X1为CR7且X2为S，（iv）X1为S且X2为CR7；（v）X1为NR8且X2为N，（vi）X1为N且X2为NR8，（vii）X1为CR7且X2为O，（viii）X1为O且X2为CR7，（ix）X1为CR7且X2为C（R7）2，（x）X1为C（R7）2且X2为CR7；（xi）X1为N且X2为O，或（xii）X1为O且X2为N，对于抑制脂质激酶包括p110α和其他PI3K的亚型，并用于治疗由脂质激酶介导的癌症等疾病是有用的。公式I化合物的使用方法，用于哺乳动物细胞中的体外、原位和体内诊断、预防或治疗此类疾病，或相关的病理条件。
• BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
  申请人：Blaquiere Nicole

  公开号：US20110076291A1

  公开（公告）日：2011-03-31

  Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z 1 is CR 1 or N; Z 2 is CR 2 or N; Z 3 is CR 3 or N; Z 4 is CR 4 or N; and where (i) X 1 is N and X 2 is S, (ii) X 1 is S and X 2 is N, (iii) X 1 is CR 7 and X 2 is S, (iv) X 1 is S and X 2 is CR 7 ; (v) X 1 is NR 8 and X 2 is N, (vi) X 1 is N and X 2 is NR 8 , (vii) X 1 is CR 7 and X 2 is O, (viii) X 1 is O and X 2 is CR 7 , (ix) X 1 is CR 7 and X 2 is C(R 7 ) 2 , (x) X 1 is C(R 7 ) 2 and X 2 is CR 7 ; (xi) X 1 is N and X 2 is O, or (xii) X 1 is O and X 2 is N, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  公式I中的苯并噻吩化合物，包括立体异构体、几何异构体、互变异构体、溶剂化物、代谢物和其药学上可接受的盐，其中：Z1为CR1或N；Z2为CR2或N；Z3为CR3或N；Z4为CR4或N；当(i) X1为N且X2为S，(ii) X1为S且X2为N，(iii) X1为CR7且X2为S，(iv) X1为S且X2为CR7，(v) X1为NR8且X2为N，(vi) X1为N且X2为NR8，(vii) X1为CR7且X2为O，(viii) X1为O且X2为CR7，(ix) X1为CR7且X2为C(R7)2，(x) X1为C(R7)2且X2为CR7，(xi) X1为N且X2为O，或(xii) X1为O且X2为N，对于抑制脂质激酶，包括p110α和其他PI3K的亚型，并用于治疗由脂质激酶介导的癌症等疾病有用。本文还公开了使用公式I化合物在哺乳动物细胞中进行体外、体内和原位诊断、预防或治疗此类疾病或相关病理条件的方法。
• [EN] A2A ADENOSINE RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DE RECEPTEUR D'ADENOSINE A2A
  申请人：BIOGEN IDEC INC

  公开号：WO2004092173A3

  公开（公告）日：2004-12-09